We examined the clinical usefulness of 3 parameters of routine laboratory tests [platelet-large cell ratio (P-LCR), lactate dehydrogenase (LDH) and C-reactive protein (CRP)] in 84 patients with thrombocytosis-related diseases (reactive thrombocytosis, chronic myeloid leukemia, essential thrombocythemia and polycythemia vera). These thrombocytosis-related diseases were characterized using the 3 parameters P-LCR, LDH and CRP as follows: high P-LCR and high LDH in chronic myeloid leukemia; high CRP in reactive thrombocytosis; slightly high P-LCR and high LDH in essential thrombocythemia and polycythemia vera. For essential thrombocythemia and polycythemia vera, levels of P-LCR and CRP were nearly identical, but the LDH level in essential thrombocythemia was significantly higher than in polycythemia vera. These characteristics of P-LCR, LDH and CRP may be useful for simple and very rough differentiation of the thrombocytosis-related disease mentioned above.

Keywords:
Platelet-large cell ratio, Lactate dehydrogenase, C-reactive protein
1.
Williams WJ: Disorders of hemostasis; in Williams WJ, Beutler E, Erslev AJ, Lichtman MA (eds): Hematology, ed 4. New York, McGraw-Hill, 1990, pp 1338–1342.
2.
Marshall AL: Classification and clinical manifestations of hematopietic stem cell disorders; in Williams WJ, Beutler E, Lichtman MA, Barrys C, Kipps TJ (eds): Hematology, ed 5. New York, McGraw-Hill, 1995, pp 229–238.
3.
Kaser A, Brandacher G, Steurer W, Kaser S,Offner FA, Zoller H, Theurl L, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H: Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001;98:2720–2725.
4.
Lelie JVR, Borne AKVD: Platelet volume analysis for differential diagnosis of thrombocytosis. J Clin Pathol 1986;39:129–133.
5.
Kabutomori O, Kanakura Y, Iwatani Y: Increase in platelet-large cell ratio in chronic myeloid leukemia. Leuk Res 2001;25:873.
6.
Paydas S, Ergin M, Baslamisli F, Yavuz, S, Zorludemir S, Sahin B, Bolt FA: Bone marrow necrosis: clinicopathologic analysis of 20 cases and review of the literature. Am J Hematol 2001;70:300–305.
7.
P-LCR (platelet-large cell ratio) functional description; in Sysmex K-4500 Operator’s Manual. Kobe, Sysmex Co., 1994, pp 9–20.
8.
Jaffe E, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoiteic and Lymphoid Tissues. Lyon, IARC Press, 2001.
9.
Thiele J, Kvasnicka HM: Chronic myeloproliferative disorders with thrombocythemia: acomparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003;82:148–152.
10.
Bessman JD: The relation of megakaryocyte ploidy to platelet volume. Am J Hematol 1984;16:161–170.
11.
Jacobsson S, Carneskog J, Ridell B, Wadenvik H, Swolin B, Kutti J: Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis. Eur J Haematol 1996;56:287–292.
12.
Jacobsson S, Wadenvik H, Kutti J, Swolin B: Low megakaryocyte ploidy in Ph-positive chronic myelogenous leukemia measured by flow cytometry. Am J Clin Pathol 1999;111:185–190.
13.
Thiele J, Wagner S, Dienemann D, Wienhold S, Zankovich R, Fischer R, Stein H: An immunomorphometric study on megakaryocyte precursor cells in bone marrow tissue from patients with chronic myeloid leukemia (CML). Eur J Haematol 1990;44:63–70.
14.
Magill GB, Wroblewski F, LaDue JS: Serum lactic dehydrogenase and serum transaminase in human leukemia. Blood 1959;14:870–881.
15.
Talpaz M, McCredie K, Kantarjian H, Trujillo J, Keating M, Gutterman J: Chronic myelogeous leukamie: haematological remissions with α interferon. Br J Haematol 1986;64:87–95.
16.
Thiele J, Kvasnicka HM, Zankyovich R Diehl V: The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Hematologica 2001;86:368–374.
17.
Hehlmann R, Jahn M, Baumann B, Köpcke W: Essential thrombocythemia: clinical characteristics and course of 61 cases. Cancer 1988;61:2487–2496.
18.
Yap SH, Moshage HJ, Hazenberg BPC, Roelofs HMJ, Bijzet J, Limburg PC, Aarden LA, van Rijswijk MH: Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta 1991;1091:405–408.
19.
Uppenkamp M, Makarova E, Petrasch S, Brittinger G: Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis. Ann Hematol 1998;77:217–223.
20.
Katerina EP, Eleftheria CH, Paraskevi KB, Afroditi K, Konstantinos S, Justin S, Konstantinos LB: Serum interleukin (IL)-1,IL-2, sIL-2Ra, IL-6 and thrombopoietine levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005;130:709–715.
21.
Schafer AI: Essential thrombocythemia and thrombocytosis; in Lichtman MA, Beuttler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JF (eds): Hematology, ed 7. New York, McGraw-Hill, 2006, pp 1785–1794.
22.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench A, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR; Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
23.
Bousquet M, Le Guellec S, Quelen C, Rigal-Huget F, Delsol G, Brousset P: Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations. Hum Pathol 2006;37:1458–1464.
24.
Lippert E, Boissint M, Kralovics R, Girodon F, Dobo I, Vincent P, Boiret-Dupre N, Skoda RC, Hermouet S: The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006;108:1865–1867.
25.
Horn T, Kremer M, Dechow T, Pfeifer WM, Geist B, Perker M, Duyster J, Quintanilla-Martinez L, Fend F: Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases. J Mol Diagn 2006;8:299–304.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.